HLB Life Science Co Ltd
KOSDAQ:067630
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
8 190
23 674.8664
|
Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one HLB Life Science Co Ltd stock under the Base Case scenario is 2 184.52 KRW. Compared to the current market price of 8 280 KRW, HLB Life Science Co Ltd is Overvalued by 74%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
HLB Life Science Co Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for HLB Life Science Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
HLB Life Science Co Ltd
Balance Sheet Decomposition
HLB Life Science Co Ltd
Current Assets | 143.2B |
Cash & Short-Term Investments | 71.3B |
Receivables | 17.1B |
Other Current Assets | 54.7B |
Non-Current Assets | 350.5B |
Long-Term Investments | 214.2B |
PP&E | 83.5B |
Intangibles | 52.3B |
Other Non-Current Assets | 484.4m |
Current Liabilities | 67.9B |
Accounts Payable | 6.2B |
Short-Term Debt | 10.2B |
Other Current Liabilities | 51.4B |
Non-Current Liabilities | 66.8B |
Long-Term Debt | 62.1B |
Other Non-Current Liabilities | 4.8B |
Earnings Waterfall
HLB Life Science Co Ltd
Revenue
|
92.9B
KRW
|
Cost of Revenue
|
-95.4B
KRW
|
Gross Profit
|
-2.5B
KRW
|
Operating Expenses
|
-24.4B
KRW
|
Operating Income
|
-27B
KRW
|
Other Expenses
|
17.8B
KRW
|
Net Income
|
-9.2B
KRW
|
Free Cash Flow Analysis
HLB Life Science Co Ltd
KRW | |
Free Cash Flow | KRW |
Profitability Score
Profitability Due Diligence
HLB Life Science Co Ltd's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
HLB Life Science Co Ltd's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
HLB Life Science Co Ltd's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
HLB Life Science Co Ltd's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
HLB Life Science Co Ltd
Dividends
Current shareholder yield for HLB Life Science Co Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
HLB Life Sciences Co., Ltd. engages in the provision of energy saving services. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2008-11-25. Along with subsidiaries, the Company operates its business through four segments. The Pharmaceutical Distribution segment is involved in the sale of pharmaceuticals and raw materials through SHINWHAADVANCE.CO.LTD. The Energy Business segment is engaged in energy service company (ESCO) business. The company is equipped with equipments, assets and technical personnel to engage in energy saving investment business. The Bio Development segment is engaged in the development of extracorporeal circulation type bio space, hepatocyte treatment agents and hemostatic agents. The main products include anticancer drugs such as Tegatrabetan and Seclidemstat. The Other Business segment is involved in the investment of small business start-ups and venture businesses, as well as manufacturing and sale of light emitting diode (LED) products.
Contact
IPO
Employees
Officers
The intrinsic value of one HLB Life Science Co Ltd stock under the Base Case scenario is 2 184.52 KRW.
Compared to the current market price of 8 280 KRW, HLB Life Science Co Ltd is Overvalued by 74%.